New eye treatment effective in laboratory tests

A promising technique for treating human eye disease has proven effective in preclinical studies and may lead to new treatments to prevent blindness, according to experiments conducted at The Scripps Research Institute (TSRI) in La Jolla, California.

The studies involved controlling the actions of microRNAs, tiny pieces of RNA that were once considered to be "junk" but are now known to fine-tune gene activation and expression. The researchers showed that treating mice with short RNA strands that precisely target and inhibit microRNAs ("antimicroRNAs") can stop the aberrant growth of blood vessels ("neovascularization").

It is this abnormal proliferation of vessels that exacerbates vision loss in neovascular eye diseases like "wet" macular degeneration and diabetic retinopathy, two of the leading causes of blindness.

Described in the cover story of the November issue of the Journal of Clinical Investigation, the microRNA treatments blocked aberrant vessel growth without damaging existing vasculature or neurons in three separate models of neovascular eye disease - a proof-of-principle that suggests future treatment based on the same approach may be effective in humans.

"We believe that targeting and inhibiting the action of microRNAs involved could represent a novel and effective way to treat a broad range of neovascular eye diseases such as diabetic retinopathy, macular degeneration and macular telangiectasia," said TSRI Professor Martin Friedlander, MD, PhD, who was senior author of the study. "We are excited about this approach to halting abnormal blood vessel growth without inducing off-target side effects."

The work is the first published result of a five-year, $10.2 million grant awarded last year by the National Eye Institute of the National Institutes of Health. The grant aims to harness the potential of microRNAs to stop abnormal blood vessel sprouting in the back of the eye and prevent blindness.

Friedlander said that the researchers hope to advance this approach with clinical trials; a potential pharmaceutical partner is interested in partnering with them once the therapy is optimized for human use. Clinical trials may take several years, and any such treatment would have to prove safe and effective before it would be routinely available.

"Are we ready to go to the clinic tomorrow? - no," said Friedlander. "But is this class of therapeutics 'druggable' - the answer is 'yes.'"

Diseases Tied to Protein Called VEGF

Many types of blindness can be tied directly to the abnormal growth of blood vessels in the back of the eye - the retina, a soft tissue already rich with vasculature and crowded with light-sensing cells that capture visual cues and send signals to the brain.

In diseases like "wet" macular degeneration and diabetic retinopathy, abnormal blood vessels proliferate under or on top of the retina, respectively, presumably in response to hypoxia, or low oxygen levels. While the precise cause of the hypoxia is not clear, in the case of macular degeneration it may be due to deposits of abnormal molecules leading to inflammation and neovascularization. In diabetic retinopathy, scientists believe that the vessels themselves function abnormally, leaking fluid and bleeding, leading to loss of vision and the growth of additional abnormal vessels.